Skip to content
July 21, 2026

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue